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ABSTRACT 
Objective: Anthralin is one of the most effective drugs in psoriasis management. However, its side effects and unfavourable physicochemical 
properties limit its clinical use. Therefore, the objective of this study was to prepare and evaluate poly (ethylene glycol)-block-poly (ε-caprolactone) 
(PEG-b-PCL) nanoparticles as a potential delivery system for anthralin. 
Methods: PEG-b-PCL nanoparticles were prepared by the co-solvent evaporation method and evaluated using a variety of techniques. The effect of 
drug/polymer weight feed ratio on the nanoparticle size, drug loading capacity and encapsulation efficiency were studied. Drug release kinetics was 
studied using the dialysis bag method. Nanoparticle size was measured using dynamic light scattering and confirmed by transmission electron 
microscopy measurements.  
Results: PEG-b-PCL formed spherical nanoparticles having a diameter of 40 to 80 nm based on the polymer and level of drug loading. The size 
observed by TEM measurements was slightly smaller than that obtained by DLS due nanoparticle dryness during measurement. Drug loading 
capacity increased with increasing the drug/polymer ratio and a maximum loading of ~25% was obtained. Anthralin encapsulation in the nano 
particles resulted in ~120-fold increase in its aqueous solubility. Anthralin was released from the nanoparticles over a prolonged period of time 
where ~ 45% was released in 48 h.  
Conclusion: These results confirm the utility of PEG-b-PCL nanoparticles in enhancing the aqueous solubility and sustaining the release of athralin. 
Therefore, they might be used as a potential delivery system for the treatment of psoriasis.  
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INTRODUCTION 
Psoriasis is a common, incurable and chronic inflammatory skin 
disease that is associated with a number of significant co-
morbidities, such as cardiovascular diseases and seronegative 
arthritis known as psoriatic arthritis [1]. It is now recognized as one 
of the most common immune-mediated disorders where tumor 
necrosis factor alpha, dendritic cells, and T-cells considerably 
contribute to its pathogenesis [2]. It occurs in 2–3% of the 
population of the United Kingdom (UK) and in 3.2% of US adults 
ages 20 y and older [2, 3]. Early onset disease that affects patients at 
age<40 y accounts for more than 75% of psoriasis cases [2]. Genetic 
predisposition, in addition to environmental triggers, such as beta-
haemolytic streptococcal infections or stress are major determinants 
of early-onset disease prognosis [1, 2]. Psoriasis can negatively 
impact patient quality of life and lead to substantial morbidity and 
mortality[4]. Reduction of the quality of life in psoriasis patients is 
comparable to that in patients with diabetes, heart diseases and 
cancer [5]. Depression is significantly higher in psoriasis patients 
than in the general population and leads to an increased incidence of 
suicidal attempts [6]. Therefore, a safe and effective therapy of 
psoriasis is highly desirable.  
Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 
y ago has shown excellent efficacy in the management of psoriasis 
[7, 8]. However, anthralin administration is associated with 
numerous side effects that discourage its wide-spread use. For 
instance, topical application of anthralin results in skin irritation, 
stinging, burning, redness and staining of the skin and clothes. 
Further, anthralin is chemically unstable and is readily degraded by 
photo-oxidation [9, 10]. The literature shows several attempts to 
overcome these shortcomings while maintaining or increasing drug 
efficacy. For instance, shorter application time has been 
recommended followed by washing the skin with special cleansing 
agents [11, 12]. Aqueous cream and wax-ester-based preparations of 
anthralin have also been recommended [13, 14]. However, anthralin 
clinical utility remains limited in spite of these modifications. 
Therefore, efficient drug delivery systems able to minimize anthralin 
side effects and maximize its efficacy remain yet to be developed.  
Pharmaceutical nanotechnology has emerged as an effective tool in 
improving drug efficacy while minimizing its side effects [15]. 
Because of their nanometric size and unique core-shell structure, 
nanoparticles have enhanced penetration through the tissue 
barriers, in addition to maximum drug protection against harsh 
conditions, in vitro and in vivo [16]. Thus, anthralin encapsulated 
into liposomes and niosomes showed significantly enhanced 
permeation through mouse abdominal skin [9]. Further, anthralin 
liposomes showed minimum skin irritation and staining of skin and 
clothes. Markedly low incidence and severity of perilesional 
erythema and skin staining were seen with anthralin liposomes in 
comparison with anthralin conventional cream [8]. However, 
liposomes suffer from many disadvantages such as chemical 
instability of phospholipids and liposome tendency to degrade, 
aggregate and fuse. This can cause premature drug release during 
storage and after administration [17]. 
The aim of the present work was to prepare and evaluate PEG-b-PCL 
nanoparticles and test their potential as a delivery system for 
anthralin. The nanoparticle size, drug content and drug release were 
evaluated using different techniques.  
MATERIALS AND METHODS 
Materials 
Anthralin was purchased from Professional Compounding Centers of 
America (Houston, TX, USA). Dialysis membranes (Spectra/por, 
MWCO: 3.5-5 kDa, unless otherwise indicated) were purchased from 
Fisher Scientific (Rancho Dominguez, CA, USA). Poly (ethylene 
glycol)-block-poly (ε-caprolactone) (PEG-b-PCL) copolymers were 
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obtained from Polymer Source (Dorval, QC, Canada). Two polymers 
were purchased, namely PEG2-b-PCL5 and PEG2-b-PCL10 where 
PEG molecular weight was 2 kDa, and the PCL molecular weight was 
either 5 or 10 kDa, respectively. All other chemicals were reagent 
grade and used as received.  
Preparation of empty and anthralin-loaded nanoparticles 
Drug-loaded nanoparticles were prepared by the co-solvent 
evaporation method [18-20]. Empty nanoparticles were prepared by 
the same method and used as a control. Specific weights of the 
polymer and drug (drug/polymer ratio of 0–50 wt. %) were 
dissolved in 1.5 ml of acetone [21, 22]. This solution was added 
dropwise (1 drop/10 s) to 3 ml of magnetically stirred water 
adjusted to pH 3.3. The mixtures were stirred in open vials for 24 h 
to remove acetone and trigger nanoparticle formation. 
Subsequently, the mixtures were filtered through a 0.45 μm PVDF 
filter to remove the free (non-incorporated) drug and the 
nanoparticle solution was characterized by different techniques. 
Final polymer concentration in water was 10% w/v.  
Determination of nanoparticle size by dynamic light scattering 
The dynamic light scattering measurements were performed on a 
Malvern ZetaSizer (Nano-ZS, Malvern Instruments, Worcestershire, UK). 
The instrument was equipped with a He-Ne laser operating at 633 nm 
and an avalanche photodiode detector. Samples were filtered through a 
0.45 μm Millex Millipore PVDF membrane prior to measurements to 
remove dust particles. The mean hydrodynamic diameter and 
polydispersity index of the nanoparticles were determined. 
Measurements were performed in triplicates at room temperature. A 
cumulant analysis was applied to obtain the hydrodynamic diameter and 
polydispersity index of the nanoparticles. The constrained regularized 
CONTIN method was used to obtain the particle size distribution. 
Measurement of nanoparticle size by transmission electron 
microscopy 
Transmission electron microscopy (TEM) images of the 
nanoparticles were taken using a Phillips CM200 electron 
microscope equipped with an AMT 2k × 2k CCD camera at an 
acceleration voltage of 80 kV. TEM samples were prepared by 
adding 15 μl of the aqueous nanoparticle solutions onto a Formvar-
coated 400 mesh grid stabilized with evaporated carbon film. The 
nanoparticles were negatively stained by adding 15 μl of 1% 
aqueous uranyl acetate solution. The samples were allowed to dry 
overnight at room temperature. 
Determination of drug encapsulation efficiency and loading 
capacity  
Aliquots of the anthralin-loaded nanoparticle solution were diluted 
10 times by acetonitrile and used to determine drug content of the 
particles by measuring the UV absorbance at 349 nm and using a 
calibration curve. Empty nanoparticle samples were treated 
similarly and used as a control. Anthralin encapsulation efficiency 




Drug release studies 
In vitro release of anthralin from PEG-b-PCL nanoparticles was 
studied by the dialysis bag method in citrate buffer pH 3.3. The 
buffer contained 2% sodium lauryl sulfate and 20% methanol due to 
the very limited solubility of anthralin in aqueous media [9]. 
Aliquots of anthralin nanoparticle solutions in water pH 3.3 
(1 ml, [anthralin] = 1.0–1.50 mg/ml) were introduced in a dialysis 
tube (MWCO = 3.5–5 kDa). The solution was dialyzed against 25 ml 
of the release medium maintained at 37 °C. At predetermined time 
intervals, aliquots were taken and replaced by fresh release medium 
maintained at 37 °C. The concentration of the drug in the release 
samples was determined from its UV absorbance at 349 nm and 
using a previously constructed calibration curve. The cumulative 
percent of drug released was plotted as a function of dialysis time. 
RESULTS AND DISCUSSION 
Preparation and evaluation of anthralin nanoparticles 
Anthralin is an unstable hydrophobic drug with an aqueous 
solubility ≤ 2 µg /ml [9]. The nanoparticles were prepared in an 
aqueous solution of pH 3.3 due to the drug instability at higher pH 
values. PEG-b-PCL copolymers are known to form nanoparticles 
having a hydrophobic PCL core surrounded by a PEG corona [21]. 
Anthralin incorporation into the hydrophobic cores of PEG-b-PCL 
nanoparticles could enhance its aqueous solubility, sustain its 
release and protect it against photolytic degradation [9]. Blank and 
anthralin-loaded nanoparticles were prepared by the co-solvent 
evaporation method, which is proven useful for the incorporation 
of many hydrophobic drugs [18, 20]. DLS measurements were 
used to ascertain the formation of nanoparticles and characterize 
their size and polydispersity. Fig.1 shows the size distribution of 
anthralin-loaded PEG2-b-PCL5 and PEG2-b-PCL10 nanoparticles. 
The nanoparticles had narrow size distribution indicating 
uniformity of size and absence of aggregates. This was further 
confirmed by measuring the polydispersity index (PDI) of the 
nanoparticles which was ≤ 0.25 confirming the monodispersity of 
the nanoparticles [23]. The nanoparticle shape and morphology 
were studied by TEM measurements (fig. 2). A TEM image of the 
nanoparticles F6 (PEG2-b-PCL5 containing ~20% w/w anthralin) 
shows that the nanoparticles are spherical, well-dispersed and 
free of aggregates. The average size obtained from this TEM image 
is 67.8±6.9 nm, which is slightly smaller than that obtained by DLS 
due to the drying of the nanoparticles during sample preparation. 
This difference is because TEM gives the size of the dry 
nanoparticles while DLS measures the hydrodynamic diameter of 
the particles in solution [24, 25]. 
 
 
Fig. 1: Distribution of the hydrodynamic diameter of (A): anthralin-loaded PEG2-b-PCL5 nanoparticles and (B): anthralin-loaded PEG2-b-
PCL10 nanoparticles (Solvent: water pH 3.3; polymer concentration: 1.0 g/l; anathralin/polymer ratio: 30 wt.%) 
Anthralin loading capacity (weight %) = weight  of  anthralin  in  nanoparticles
Total  weight  of  nanoparticles  tested
 × 100                                           
Anthralin encapsulation efficiency (weight %) = weight  of  anthralin  in  nanoparticles
Total  weight  of  anthralin  used  initially
 × 100                
Soliman et al. 




Fig. 2: TEM image of PEG2-b-PCL5 nanoparticles prepared by 
the cosolvent evaporation method at polymer concentration of 
1.0 mg/ml and drug/polymer weight ratio of 20% 
 
The nanoparticles were prepared at different drug/polymer ratios 
and their drug loading capacity and encapsulation efficiency were 
determined. Table 1 shows the drug loading capacity and 
encapsulation efficiency for anthralin/PEG2-b-PCL5 nanoparticles. 
The drug loading capacity increased with the increase in 
drug/polymer weight ratio. A similar trend was observed for the 
anthralin encapsulation efficiency (table 1). Thus, increasing the 
drug/polymer weight ratio from 10 to 50% resulted in increasing 
the drug loading capacity from 3.26±0.21 to 19.05±0.42%. This was 
associated with increasing anthralin aqueous solubility to ~ 190 
µg/ml. This represents ~ 95-fold enhancement in anthralin aqueous 
solubility. Table 2 shows the drug loading capacity and 
encapsulation efficiency for anthralin/PEG2-b-PCL10 nanoparticles. 
Similar to PEG2-b-PCL5 nanoparticles, the drug loading capacity and 
encapsulation efficiency increased with increasing the drug/polymer 
ratio. However, the drug loading capacity and drug solubility 
obtained for the nanoparticles prepared at drug/polymer weight 
ratio of 50% were higher for PEG2-b-PCL10 nanoparticles. Thus, 
anthralin aqueous solubility obtained under these conditions was ~ 
240 µg/ml, which represents about 120-fold enhancement in the 
aqueous drug solubility. It is noteworthy that the limited anthralin 
solubility in some conventional bases, such as soft paraffin results in 
the incorporation of extra drug concentrations in its crystalline form 
to maintain the therapeutic drug effect. However, the insoluble form 
of the drug causes irritation and staining of normal skin [9]. 
Therefore, the extraordinary anthralin loading and enhancement of 
aqueous solubility achieved by PEG-b-PCL nanoparticles are 
expected to be advantageous in overcoming the drug shortcomings. 
  
Table 1: Composition and properties of blank and anthralin-loaded PEG2-b-PCL5 nanoparticles 
Formulation code Drug/polymer (wt%) % LCa % EEb 
F1 0 - - 
F2 10 3.26±0.21 32.62±2.08 
F3 20 6.80±0.25 34.01±1.25 
F4 30 13.94±0.25 46.45±0.83 
F5 40 17.88±0.32 44.69±0.80 
F6 50 19.05±0.42 38.09±0.83 
aPercent drug loading capacity, calculated using equation 1. Mean of three measurements±SD, bPercent encapsulation efficiency, calculated using 
equation 2. Mean of three measurements±SD. 
 
Table 2: Composition and properties of blank and anthralin-loaded PEG2-b-PCL10 nanoparticles 
Formulation code Drug/polymer (wt%) % LCa % EEb 
F7 0 - - 
F8 10 3.11±0.27 31.12±2.70 
F9 20 7.20±0.26 36.01±1.31 
F10 30 11.88±0.29 39.59±0.95 
F11 40 11.60±0.46 29.01±1.14 
F12 50 24.15±0.82 48.29±1.65 
aPercent drug loading capacity, calculated using equation 1. Mean of three measurements±SD, bPercent encapsulation efficiency, calculated using 
equation 2. Mean of three measurements±SD. 
 
 
Fig. 3: Hydrodynamic diameter and polydispersity index as a function of drug/polymer weight ratio for (A) anthralin/PEG2-b-PCL5 
nanoparticles and (B) anthralin/PEG2-b-PCL10 nanoparticles. Nanoparticles were prepared by the co-solvent evaporation method at 
polymer concentration of 1.0 mg/ml 
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Fig. 3 shows the hydrodynamic diameter and polydispersity index of 
empty and anthralin-loaded PEG-b-PCL nanoparticles. Empty PEG2-
b-PCL5 nanoparticles had a hydrodynamic diameter of 40.3±0.28 
nm. There was a general increase in the nanoparticle size upon drug 
incorporation. Thus, the PEG2-b-PCL5 nanoparticle size increased 
from 40.3±0.28 to76.3±1.10 nm upon incorporation of ~20% drug 
(fig. 3A). Similar trend was observed for PEG2-b-PCL10 
nanoparticles (fig. 3B). The increase in nanoparticle size upon drug 
loading might be due the drug encapsulation in the nanoparticle core 
resulting in their expansion to accommodate the loaded drug [18, 
21, 26]. In general, PEG2-b-PCL5 nanoparticles were smaller in size 
compared to those of PEG2-b-PCL10 [27]. This might be attributed 
to the bigger PCL segment molecular weight in PEG2-b-PCL10. The 
PCL segment forms the nanoparticle core and therefore longer PCL 
chains result in the formation of bigger nanoparticles. 
Drug release studies 
Anthralin release from the nanoparticles was studied by the dialysis 
bag method which is widely used for studying drug release from 
nanoparticles [28-30]. Fig.4 shows the release rate as a function of 
time of anthralin from PEG2-b-PCL5 and PEG2-b-PCL10 nanoparticles. 
The release pattern was similar for both nanoparticle formulations 
indicating that the drug release rate is affected neither by the polymer 
molecular weight nor by the level of drug loading. Similar behavior 
was noticed previously for other drug-loaded nanoparticle systems 
[20]. Anthralin release was slow in both nanoparticle systems where 
only ~ 45% was released in 48 h. The slow release might be attributed 
to the hydrophobic nature of the drug which facilitates its hydrophobic 
interactions with the core-forming segments of the copolymers. 
Sustained release is beneficial in reducing the frequency of drug 
administration and thus improving patient compliance.  
 
 
Fig. 4: Cumulative percent anthralin released from PEG2-b-PCL5 
and PEG2-b-PCL10 nanoparticles in citrate buffer pH 3.3 at 37 °C 
 
CONCLUSION 
PEG-b-PCL block copolymer nanoparticles were used as a potential 
delivery system for anthralin for the treatment of psoriasis plaques. 
Anthralin was loaded into the nanoparticles by a simple, yet effective 
method which resulted in drug loading capacity up to ~ 25 wt.% for 
PEG2-b-PCL10 nanoparticles. This was accompanied by ~ 120-fold 
increase in anthralin aqueous solubility. The formed nanoparticles 
had a spherical shape and were uniform in size and shape. The 
nanoparticle size was dependent on the polymer used and level of 
drug loading, where higher drug loading resulted in bigger particle 
size. Drug release from the nanoparticles was slow confirming the 
ability of the nanoparticles to sustain the drug release. These results 
confirm the potential of PEG-b-PCL nanoparticles as an effective 
delivery system for anthralin in the treatment of psoriasis.  
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